<DOC>
	<DOCNO>NCT01460654</DOCNO>
	<brief_summary>This study investigate hypothesis combination testosterone replacement alendronate improve bone density parameter bone quality either medication alone old men low testosterone level low bone density .</brief_summary>
	<brief_title>Testosterone Alendronate Hypogonadal Men</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male sex Age 60 Testosterone &lt; 300 ng/dL DXA T score &lt; 1 OR FRAX Score 3 % great hip fracture 20 % great major osteoporotic fracture Significant liver kidney disease Elevated prolactin level Abnormal TSH Abnormal 25Vitamin D PSA &gt; 2.5 History malignancy Calcium &gt; 10.6 Alkaline Phosphatase &gt; 150 Fracture within last 6 month History acute urinary retention Hematocrit &lt; 32 % &gt; 50 % Fracture within past 6 month American Urological Association BPH symptom index &gt; 21 Sleep apnea Abnormalities esophagus delay esophageal empty Significant cardiopulmonary disease</criteria>
	<gender>Male</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>